دورية أكاديمية

Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry.

التفاصيل البيبلوغرافية
العنوان: Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry.
المؤلفون: Martino, M, Ballestrero, A, Zambelli, A, Secondino, S, Aieta, M, Bengala, C, Liberati, A M, Zamagni, C, Musso, M, Aglietta, M, Schiavo, R, Castagna, L, Rosti, G, Bruno, B, Pedrazzoli, P
المصدر: Bone Marrow Transplantation; Mar2013, Vol. 48 Issue 3, p414-418, 5p, 1 Chart, 4 Graphs
مصطلحات موضوعية: BREAST cancer patients, CANCER in women, METASTASIS, HEMATOPOIETIC stem cell transplantation, COMPLICATIONS from organ transplantation, HOMOGRAFTS
مستخلص: The median survival of women with metastatic breast cancer (MBC) is 18-24 months, and fewer than 5% are alive and disease free at 5 years. We report toxicity and survival in a cohort of MBC patients receiving high-dose chemotherapy (HDC) with autologous hematopoietic SCT (AHSCT) in Italy between 1990 and 2005. Data set for survival analysis has been obtained for 415 patients. Clinical parameters including probability of transplant-related mortality (TRM), PFS and OS. With a median follow-up of 27 months (range 0-172), OS and PFS at 5 and 10 years in the whole population were 47/23 and 32/14%, respectively. A total 239 patients are alive with a median follow-up of 33 months (range 2-174). Survival was significantly more pronounced in patients harboring hormone receptor positive tumors (P=0.028), without visceral metastases (P=0.009) and in women with chemosensitive disease (P<0.0001). Sixty eight patients (20.4%) who received HDC in partial response, stable or progressive disease underwent conversion to CR. TRM was 2.5% overall and 1.3% since 2000. Our findings suggest that could be a role for HDC and AHSCT in delaying disease progression and possibly cure a subset of MBC patient harboring chemosensitive tumors. [ABSTRACT FROM AUTHOR]
Copyright of Bone Marrow Transplantation is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:02683369
DOI:10.1038/bmt.2012.149